Amrutanjan Health Care Q1 FY26 earnings call: Revenue & Margins
Q1 FY26 investor presentation: what the company reported on revenue, margins and capex.
- Revenue
- ₹94Cr
- +11.9% YoY
- −30.4% QoQ
- Net profit
- ₹8Cr
- +60% YoY
- −46.7% QoQ
- Margin
- 9%
- +4.8 pp YoY
- −4 pp QoQ
Top 10 Pharmaceuticals & Biotechnology companies on management guidance
See the sector's top 10 — free with your mobile number.
Based on Amrutanjan Health Care Ltd's Q1 FY26 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.
The short version
Overall Financial Performance Q1 FY26 vs Q1 FY25:. EBITDA/profit before tax (PBT) for Q1 FY26: Rs. 11.29 Cr, up 77.80% YoY (from Rs. 6.35 Cr in Q1 FY25) [Page 16].
From Amrutanjan Health Care Ltd's Q1 FY26 earnings-call transcript · updated 24 Sept 2026.
Revenue & Sales Performance
- Overall Financial Performance Q1 FY26 vs Q1 FY25:
- Net Sales: Rs. 94.05 Cr, up 12.31% from Rs. 83.74 Cr
- Gross Sales: Rs. 107.19 Cr, up 14.58% from Rs. 93.55 Cr
- Profit Before Tax: Rs. 11.29 Cr, up 77.80% from Rs. 6.35 Cr
- Profit After Tax: Rs. 8.31 Cr, up 79.87% from Rs. 4.62 Cr
- Category-wise Sales Growth:
- OTC Gross Sales: Rs. 96.79 Cr, up 20.19% from Rs. 80.53 Cr
- Comfy Gross Sales: Rs. 30.59 Cr, up 10.75% from Rs. 27.62 Cr
- Beverages Gross Sales: Rs. 9.69 Cr, down from Rs. 12.88 Cr (decline)
- Electro Plus Sales: Rs. 8.70 Cr, down from Rs. 10.44 Cr (decline)
- Volume Growth:
- Pain Management head ache care segment back to double-digit volume growth; Head category volume growth 6.8% YoY; Body category volume growth 24.6% YoY.
- Roll on category growing with market leadership; competition entry shows category attractiveness.
- Outlook:
- Focus on increasing operating profit margin (EBIT) from 11.44% to 13% by revenue growth and operational efficiency.
2 more points from Amrutanjan Health Care Ltd's call on revenue
Create a free account to keep reading this call
Profitability & Margins
See what Amrutanjan Health Care Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
See what Amrutanjan Health Care Ltd said on capital expenditure plans — free account, 30 seconds.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Amrutanjan Health Care Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
See what Amrutanjan Health Care Ltd said on order book & pipeline — free account, 30 seconds.
Amrutanjan Health Care Ltd — Quarterly revenue & net profit
Amrutanjan Health Care Ltd Q1 FY26 results — key figures
| ₹ Cr | Q1 FY26 | Q1 FY25 | YoY | Q4 FY25 | QoQ |
|---|---|---|---|---|---|
| Revenue | 94 | 84 | +11.9% | 135 | -30.4% |
| Operating profit (EBITDA) | 8 | 4 | +100% | 18 | -55.6% |
| Operating margin | 9% | 4.2% | +4.8 pp | 13% | -4 pp |
| Profit before tax | 11 | 6 | +83.3% | 21 | -47.6% |
| Net profit (PAT) | 8 | 5 | +60% | 15 | -46.7% |
| EPS (₹) | 2.87 | 1.60 | +79.4% | 5.25 | -45.3% |
Source: reported quarterly figures (Screener), ₹ crore.
Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹135 Cr, net profit ₹17 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Amrutanjan Healt's management said in earlier quarters
- Q2 FY27 earnings call analysis →
- Q2 FY25 earnings call analysis →
- Q1 FY25 earnings call →
- Q4 FY24 earnings call analysis →
Earlier calls (1)
Others in Pharmaceuticals & Biotechnology this season
- RPG Life Sciences (Q1 FY26)
168.9 crores vs Rs. Key concall takeaways from RPG Life Sciences Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- SMS Pharmaceuticals (Q1 FY26)
Q1FY26 revenue from operations: ₹196.05 crore . Key concall takeaways from SMS Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
- Morepen Laboratories (Q1 FY26)
Crores)**: . Key concall takeaways from Morepen Laboratories Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
- NGL Fine Chem (Q1 FY26)
Q1FY26 Revenue from operations: ₹104.19 crores . Key concall takeaways from NGL Fine Chem Ltd's Q1 FY26 earnings call — and how it ranks against sector peers.
Potential multibaggers · Q2 FY27
Potential multibaggers in Pharmaceuticals & Biotechnology
on management's own guidance
- Strong growth2
- Strong growth1
- Strong growth3
Portfolio builder
Build your portfolio
from the top-ranked stocks
- 1. Pick 3–15 stocks
- 2. Choose large, mid or small cap and your sectors
- 3. Get a portfolio built from the rankings
Ranks describe management commentary on revenue and margin from the latest earnings call. Not investment advice.
Arthneeti Pro · Annual
Amrutanjan Health Care Ltd and 15K+ more earnings calls,
for less than your morning chai
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Amrutanjan Health Care Ltd Q1 FY26 results?
Overall Financial Performance Q1 FY26 vs Q1 FY25:. EBITDA/profit before tax (PBT) for Q1 FY26: Rs. 11.29 Cr, up 77.80% YoY (from Rs. 6.35 Cr in Q1 FY25) [Page 16].
What is Amrutanjan Health Care Ltd share price analysis?
Amrutanjan Health Care Ltd currently shows a neutral. The stock trades at a P/E of 22.9 with a market cap of ₹1,428 Cr. Investors should review the full earnings analysis for detailed insights.
Keep Amrutanjan Health Care Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
